The Growing Problem of Obesity and the Heart

Litwin, Sheldon E.

doi:10.1016/j.jacc.2005.11.014

Cited by 16 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One major mechanism by which obesity may influence LV geometry and the subsequent development of eccentric hypertrophy is through the enlargement of the left ventricle [36]. This process may be influenced by increased hemodynamic load [37], decreased LV myocardial contractility, and inflammatory activity that promotes cardiac remodeling [38].…”

Section: Discussionmentioning

confidence: 99%

Which measures of adiposity predict subsequent left ventricular geometry? Evidence from the Bogalusa Heart Study

Gustat

et al. 2015

Nutrition, Metabolism and Cardiovascular Diseases

View full text Add to dashboard Cite

Background and aims Left ventricular (LV) hypertrophy increases the risk of future cardiovascular events. The relationship between obesity in young adulthood and later LV geometry is unknown. We examined the association between long-term changes in measures of adiposity and subsequent LV geometry among 1073 young adults from the Bogalusa Heart Study. Methods and results Echocardiography-measured LV geometry was classified into normal (N = 796), concentric remodeling (N = 124), eccentric hypertrophy (N = 99), and concentric hypertrophy (N = 54) by integrating relative wall thickness and LV mass index. The mean age of our population was 38 years when the LV geometry was measured. Body mass index (BMI) increased by a mean of 4.9 kg/m2 over a median of 20 years, waist circumference (WC) by 10.9 cm over 17 years, waist/hip ratio by 0.02 over 10 years, waist/height ratio by 0.06 over 17 years, abdominal height by 0.9 cm over 10 years, body fat (BF) percentage by 12.7% over 20 years, and Visceral Adiposity Index by 0.30 over 17 years. In polytomous logistic regression models corrected for multiple comparisons, participants with one-standard-deviation increases in BMI,WC, waist/height ratio, and BF had 2.00 (95% confidence interval (CI): 1.53–2.61), 1.33 (1.06–1.68), 1.35 (1.07–1.70), and 1.60 (1.26–2.03) times the risk of eccentric hypertrophy, respectively, after adjustment for demographic, lifestyle, metabolic risk factors, and follow-up time. Likewise, the rates of change in BMI, WC, waist/height ratio, and BF were associated with eccentric hypertrophy. There was no association with concentric remodeling or concentric hypertrophy. Conclusions Our findings suggest that increases in BMI, WC, waist/height ratio, and BF were strong predictors of eccentric hypertrophy in middle age.

show abstract

Section: Discussionmentioning

confidence: 99%

Which measures of adiposity predict subsequent left ventricular geometry? Evidence from the Bogalusa Heart Study

Gustat

et al. 2015

Nutrition, Metabolism and Cardiovascular Diseases

View full text Add to dashboard Cite

show abstract

“…Over 14 years of follow up, Framingham investigators found a 5 to 7% increase in relative risk of developing heart failure for each increase of one unit in BMI [25]. Obesity can lead to LV dilatation by multiple mechanisms including excessive vascularity of adipose tissue, increasing total blood volume, and cardiac output [26]. Obesity can also cause accumulation of lipid around myocytes with resulting lipotoxicity.…”

Section: Discussionmentioning

confidence: 99%

Obesity and Left Ventricular Dilatation in Young Adulthood: The Bogalusa Heart Study

Bazzano

Belame

Patel³

et al. 2011

Clinical Cardiology

View full text Add to dashboard Cite

Background: Cardiac enlargement is an important predictor of adverse cardiovascular (CV) events. Left ventricular (LV) dilatation is a precursor both of LV dysfunction and clinical heart failure. The present study examines risk factors for LV dilatation among 832 young adults (341 male, 491 female) who participated in the Bogalusa Heart Study. Hypothesis: A unique set of risk factors predicts LV dilatation among young adults. Methods: Standard ventricular dimensions were determined by M-mode echocardiography and indexed to height using a standard method. LV dilatation was considered as the top 20th percentile of LV end-diastolic dimension indexed to height. Logistic regression models were used, stratified by race and sex, to assess the relationship of CV risk factors with quintile of LV end-diastolic dimension indexed to height. Results: The mean age (standard deviation) of men and women in the population was 36.4 years (3.9 years) and 35.9 years (4.6 years), respectively. In sex-specific models adjusted for age, race, systolic and diastolic blood pressure, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, and glycosylated hemoglobin, body mass index (BMI) was a significant predictor of LV dilatation in both men and women. The odds ratio (95% confidence interval) for a 1-unit change in BMI was 1.12 (1.02-1.19) in men and 1.09 (1.05-1.13) in women. Among men, triglyceride level was also significantly associated with LV dilatation (P = 0.03), whereas among women there was no such association. Conclusions: Our findings indicate that obesity is the most consistent predictor of LV dilatation in both men and women, whereas triglyceride level was a significant predictor among men only.

show abstract

“…Obesity is a well-established risk factor for cardiovascular disease [Litwin, 2006]. Therefore any intervention that treats obesity has the potential to improve cardiovascular risk.…”

Section: Vildagliptinmentioning

confidence: 99%

Treating type 2 diabetes: incretin mimetics and enhancers

Janosz

Zalesin

Miller

et al. 2009

Therapeutic Advances in Cardiovascular Disease

View full text Add to dashboard Cite

As a consequence of excess abdominal adiposity and genetic predisposition, type 2 diabetes is a progressive disease, often diagnosed after metabolic dysfunction has taken hold of multiple organ systems. Insulin deficiency, insulin resistance and impaired glucose homeostasis resulting from beta-cell dysfunction characterize the disease. Current treatment goals are often unmet due to insufficient treatment modalities. Even when combined, these treatment modalities are frequently limited by safety, tolerability, weight gain, edema and gastrointestinal intolerance. Recently, new therapeutic classes have become available for treatment. This review will examine the new therapeutic classes of incretin mimetics and enhancers in the treatment of type 2 diabetes.

show abstract

The Growing Problem of Obesity and the Heart

Cited by 16 publications

References 19 publications

Which measures of adiposity predict subsequent left ventricular geometry? Evidence from the Bogalusa Heart Study

Which measures of adiposity predict subsequent left ventricular geometry? Evidence from the Bogalusa Heart Study

Obesity and Left Ventricular Dilatation in Young Adulthood: The Bogalusa Heart Study

Treating type 2 diabetes: incretin mimetics and enhancers

Contact Info

Product

Resources

About